
- Applied Clinical Trials-01-01-2012
- Volume 21
- Issue 1
Rising Proportion of New and Modified Indication Approvals
Tufts Center for Drug Development
In an effort to extend product life cycles and generate larger and longer revenue streams per product, pharmaceutical and biotechnology companies have stepped up their efforts to seek approval for new or modified indications of already approved drugs.
A recent study conducted by the Tufts Center for the Study of Drug Development finds that the number of new or modified indication approvals following the original new drug approval (NDA) increased 17% between the periods 1998 to 2003 and 2004 to 2009. Original NDAs as a proportion of total drug approvals continues to decline gradually. The number of new drug approvals for pediatric indications following original NDAs rose sharply, increasing 107% between 1998 and 2009. The number of NDA new indications increased 15%, and the number of supplemental NDA new indications declined 5% during this period. Anti-infective and CNS drugs each accounted for one-fifth of all new or modified indication approvals between 1998 and 2009. Cardiovascular and oncology drugs accounted for 15% and 13% of all new or modified indications respectively. Moving forward, with finite resources, sponsors must strike the right balance in maximizing portfolio value by allocating R&D resources between novel, original NDAs, and new or modified indication approvals.
—Tufts Center for the Study of Drug Development,
Articles in this issue
almost 14 years ago
Applied Clinical Trials Digital Edition - January 2012almost 14 years ago
Risk & Resources to Shape Trial Operationsalmost 14 years ago
CV Safety for Developersalmost 14 years ago
Risk-based Approach to Monitoringalmost 14 years ago
Limited Resource Trialsalmost 14 years ago
Imaging Pharmacovigilance Needs Overhaulalmost 14 years ago
Refined Safety Assessmentsalmost 14 years ago
Biotech's Long Road to SavvyNewsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.